Clinical Trials Browser

Phase 2 × Naltrexone × Genitourinary × Clear all

NCT07224009 2026-03-02

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Phase 2 Not yet recruiting

Prostatic Neoplasms